Reactivation of the androgen receptor (AR) during androgen depletion therapy (ADT) underlies castration-resistant prostate cancer (CRPCa). Alternative splicing of the AR gene and synthesis of constitutively active COOH-terminally truncated AR variants lacking the AR ligand-binding domain has emerged as an important mechanism of ADT resistance in CRPCa. In a previous study, we demonstrated that altered AR splicing in CRPCa 22Rv1 cells was linked to a 35-kb intragenic tandem duplication of AR exon 3 and flanking sequences. In this study, we demonstrate that complex patterns of AR gene copy number imbalances occur in PCa cell lines, xenografts and clinical specimens. To investigate whether these copy number imbalances reflect AR gene rearrangements that could be linked to splicing disruptions, we carried out a detailed analysis of AR gene structure in the LuCaP 86.2 and CWR-R1 models of CRPCa. By deletion-spanning PCR, we discovered a 8579-bp deletion of AR exons 5, 6 and 7 in the LuCaP 86.2 xenograft, which provides a rational explanation for synthesis of the truncated AR v567es AR variant in this model. Similarly, targeted resequencing of the AR gene in CWR-R1 cells led to the discovery of a 48-kb deletion in AR intron 1. This intragenic deletion marked a specific CWR-R1 cell population with enhanced expression of the truncated AR-V7/AR3 variant, a high level of androgen-independent AR transcriptional activity and rapid androgen independent growth. Together, these data demonstrate that structural alterations in the AR gene are linked to stable gain-of-function splicing alterations in CRPCa.
INTRODUCTION
PCa initially presents as an androgen-and androgen receptor (AR)dependent disease. Therefore, suppressing the production or action of androgens, which inhibits AR transcriptional activity, leads to stabilization or regression of advanced PCa. The duration of response to androgen depletion therapy (ADT) is variable with the end point typically marked by rising serum levels of prostate specific antigen, an AR transcriptional target gene and rapid growth of PCa metastases. This transition from androgendependent to castration-resistant prostate cancer (CRPCa) is frequently due to aberrant AR re-activation despite ongoing treatment with AR-targeted therapies. 1 --4 Various mechanisms have been advanced to explain AR activation in CRPCa cells. These include AR gene amplification and/or AR protein overexpression, 5 --12 point mutations that permit promiscuous AR transcriptional responses 13 --20 and intra-tumor steroid synthesis or sequestration. 21 --24 This knowledge has driven the clinical development of new inhibitors of androgen production and AR signaling, 25 including the CYP17 inhibitor abiraterone acetate, which has been recently shown to increase overall survival in patients with metastatic CRPCa. 26 Synthesis of truncated AR variant proteins via AR alternative splicing has recently emerged as an additional mechanism of ADT resistance in PCa. 27 --31 These proteins lack the AR ligand-binding domain, display constitutive, ligand-independent transcriptional activity, and mediate androgen-independent growth of PCa cells in various model systems. 27 --31 Increased expression of the AR3 variant protein (also termed AR-V7 29 ) in PCa prostatectomy specimens is associated with biochemical recurrence following surgery. 28 In addition, increased mRNA expression of alternatively spliced AR variants in PCa bone metastases is associated with shorter survival. 32 Therefore, understanding the mechanisms leading to increased synthesis of these species could provide important prognostic information, or perhaps guide more effective use of therapies that inhibit ligand-dependent AR activity.
Truncated AR variants proteins were originally discovered and functionally characterized in the CRPCa 22Rv1 and CWR-R1 cell lines, 27 --29 and the LuCaP 86.2 PCa xenograft. 30 In 22Rv1 cells, a 35-kb AR intragenic tandem duplication is linked to altered splicing of full-length AR, as well as synthesis of truncated AR variants. 33 However, the mechanisms driving AR splicing alterations outside of the 22Rv1 model have remained elusive. Therefore, the purpose of this study was to investigate the link between AR gene structure alterations and enhanced synthesis of truncated AR variants in CRPCa.
RESULTS
AR gene structure complexity in CRPCa In a previous study, we analyzed high-resolution whole-genome copy number data from CRPCa metastasis, which implicated frequent AR copy number imbalance concurrent with AR amplification at this stage of the disease. 33 To investigate this phenomenon directly, we employed a multiplex ligation-dependent probe assay (MLPA) with probe sets targeted to coding exons in the AR gene ( Figure 1a ). This MLPA approach detected the 22Rv1 duplication involving exon 3, as well as 20-fold amplification of the AR gene in VCaP cells (Figure 1b ). Androgen-dependent PCa tissue obtained from xenografts ( Figure 1c ) or clinical specimens ( Figure 1d ) displayed one intact AR gene copy, with the exception of the LuCaP 35 xenograft, which displayed four copies of the AR gene. However, CRPCa tissue obtained from xenografts ( Figure 1c ) or autopsy specimens ( Figure 1d ) displayed frequent AR gene amplification and/or complex patterns of AR gene copy number imbalance. These data suggest that imbalances in AR gene copy number may be important for CRPCa progression.
To investigate this phenomenon in more detail, we focused on the LuCaP 86.2 xenograft, which expresses high levels of the truncated AR v567es variant arising from the mRNA splicing machinery skipping exons 5, 6 and 7. 30 LuCaP 86.2 displayed reduced genome copy number of these exons, indicating a mixed cell population with B50% of cells harboring an intragenic deletion ( Figure 1c ). Deletion-spanning PCR yielded products consistent with an intragenic deletion encompassing AR exons 5, 6 and 7 (Figures 2a and b ). Sequence analysis verified a 8579-bp deletion ( Figure 2c ) with microhomology at the 5 0 and 3 0 break fusion junctions, which signifies a non-homologous end joining mechanism of origin ( Figure 2d ). Together, these data implicate focal intragenic deletion as a novel mechanism underlying synthesis of the truncated AR v567es variant in the LuCaP 86.2 xenograft.
Stable AR mRNA splicing alterations in CRPCa CWR-R1 cells MLPA analysis indicated that the CRPCa CWR-R1 cell line does not harbor any AR gene copy number alterations, despite previous studies demonstrating that these cells express truncated AR variants. 28 To confirm altered splicing in these cells, we assessed AR mRNA isoform levels using an absolute quantification reverse transcription (RT)--PCR assay. To correct for variability in AR gene dosage and rates of AR transcription, we scaled copy number for each AR mRNA isoform relative to full-length AR. This approach revealed changes in the ratios of full-length AR mRNA and alternatively spliced AR isoforms in CRPCa CWR-R1 and 22Rv1 cells ( Figure 3b ). Conversely, androgen-dependent CWR22Pc, LNCaP and VCaP cells expressed predominantly full-length AR mRNA ( Figure 3b ). To test for plasticity in the expression of truncated AR variant expression in CWR-R1 cells, we knocked down full-length AR mRNA using an AR exon 7-targeted siRNA. No changes in truncated AR protein expression were observed following 48 h or 72 h of knock down, whereas an AR exon 1-targeted siRNA completely abolished all AR protein expression in these cells ( Figure 3c ). Similarly, no changes in truncated AR variant protein expression were observed in CWR-R1 cells following 24 h or 72 h of androgen stimulation ( Figure 3d ). These data indicate that the altered AR mRNA splicing pattern in CWR-R1 cells is stable and is unlikely an acute cellular response to manipulations of androgen or AR levels.
A novel intragenic deletion in CWR-R1 cells identified by pairedend AR gene resequencing As MLPA only interrogates AR copy number at coding exons, which represent less than 1.5% of the 180-kb AR gene, we analyzed the nucleotide sequence and structure of the entire AR locus in CWR-R1 cells using a combination of liquid-phase sequence capture and Illumina paired-end massively parallel sequencing ( Supplementary Figure 1 and Supplementary Table 1 ). Androgen-dependent CWR22Pc and CRPCa 22Rv1 cells were sequenced concurrently. As 49.9% of the AR locus is composed of repetitive DNA, 34 which precludes the design of capture baits to these regions, we were unable to obtain sequence for nearly a quarter of the AR gene using this strategy (Supplementary Table 1 ). In particular, no sequence was obtained within three 'gaps' of contiguous repetitive elements spanning 46 kb each ( Figure 4 and Supplementary Figures 1 and 2 ). Gaps 2 and 3 harbor the 5 0 and 3 0 breakpoints of the previously identified 22Rv1 tandem duplication 33 and no paired-end reads representing this structural alteration were detected (Supplementary Table 2 ). However, sequence coverage plots revealed increased copy number within this region, with transition points located within gaps 2 and 3 ( Supplementary Figures 2 and 3 ). No copy number imbalances in this region were observed in CWR22Pc or CWR-R1 cells (Supplementary Figure 2) . Point mutations and indels were observed at various frequencies in all three cell lines, including the previously-identified H874Y coding mutation at position chrX:66 943 543 (Supplementary Tables 3 --5) . However, no prevalent sequence alterations were observed in splice donor/ acceptor sequences in CWR-R1 and 22Rv1 cells ( Supplementary  Tables 4 and 5 ). Strikingly, structural variant analysis of paired-end reads using the Hydra workflow 35 identified a B48-kb intragenic deletion within AR exon 1 in a sub-population of the CWR-R1 cell line, which was also apparent from a relative decrease in sequence coverage peak height within this region (Figure 4 , Supplementary  Table 2 and Supplementary Figure 4 ). To confirm this structural alteration in CWR-R1 cells, we performed nested PCR using primers spanning the deletion (Figures 5a and b ). Sanger sequencing of cloned PCR products revealed deletion of 48 476 bp from AR intron 1 (Figures 5c and d ). Alignments of the 5 0 and 3 0 break fusion junctions demonstrated 3 bp of microhomology, implicating nonhomologous end joining as the mechanism underlying this deletion ( Figure 5e ).
To quantify the prevalence of this B48-kb deletion, we performed MLPA with probe pairs custom-designed to query copy number at regular intervals along the length of the AR gene ( Figure 6a ). MLPA probe pairs targeted within this 48-kb region displayed a B20 --30% decrease in copy number (Figure 6b ). There were no copy number alterations in this region detected by MLPA in CWR22Pc or 22Rv1 cells ( Figure 6b ), and nested PCR with deletion-spanning primers did not generate products in CWR22Pc or 22Rv1 cells (Figure 6c ). Similarly, only CWR-R1 cells yielded 76 bp Illumina sequencing reads that could be aligned to a 130-bp template harboring this specific breakpoint sequence (Supplementary Figure 5 ). Together, these data demonstrate that a 48 476-bp deletion within intron 1 of the AR gene is restricted to 20 --40% of the cells in the CWR-R1 cell line.
Enrichment for cells harboring AR intron 1 deletion during castration
The levels of truncated AR isoforms expressed in CWR-R1 cells are markedly higher when these cells are grown as xenografts in castrated mice versus intact mice. 28 All the analyses in our study had been performed with CWR-R1 cells that had been cultured in complete medium (contains androgens) for 10 --20 passages, which would allow the growth of both androgen-dependent and CRPCa cell populations. Therefore, we compared AR gene structure in early passage CWR-R1 cells (referred to as CWR-R1 early) to CWR-R1 cells that were cultured in the absence of androgens for 20 passages (referred to as CWR-R1-late). Remarkably, no copy number decrease within AR intron 1 was apparent following MLPA analysis of CWR-R1 early cells (Figure 7a ), despite a positive nested PCR signal for this deletion (Supplementary Figure 6 ). Conversely, MLPA probe signal in this region was nearly completely lost in CWR-R1 late cells (Figure 7a ), indicating that this deletion was a marker of the CRPCa cell sub-population. Consistent with this deletion underlying the AR splicing patterns in CWR-R1 cells, expression of the truncated AR 1/2/3/CE3 variant (also referred to as AR-V7 29 or AR3 28 ) was low in CWR-R1 early cells, regardless of whether they were cultured in whole serum or steroid-depleted serum (Figure 7b ). However, CWR-R1 late cells displayed high-level expression of AR 1/2/3/CE3 protein ( Figure 7b ). These changes at the protein level corresponded with a stable shift in splicing favoring the AR 1/2/3/CE3 AR mRNA isoform in CWR-R1 late versus CWR-R1 early cells ( Supplementary  Figure 7) . CWR-R1 cells cultured in the presence of androgens for 20 passages displayed an intermediate AR 1/2/3/CE3 protein expression pattern (Figure 7b ). Immunostaining of cells grown under castrate conditions demonstrated increased nuclear expression of the AR NH 2 -terminal domain versus the AR COOHterminal domain in CWR-R1 late cells, but not CWR-R1 early cells (Supplementary Figure 8 ). Together, these data demonstrate that cells harboring this B48-kb deletion within AR exon 1 display a splicing switch that favors stable, high-level expression of the truncated AR 1/2/3/CE3 variant.
To investigate whether there may be functional consequences to these differences in truncated AR variant expression, we examined AR transcriptional activity in CWR-R1 early and CWR-R1 late cells. AR transactivation in response to the synthetic androgen mibolerone was higher in CWR-R1 early cells than CWR-R1 late cells and knock down of full-length AR inhibited this androgen response in both cell lines ( Figure 7c ). Interestingly, knock down of AR expression with siRNAs targeted to either AR exon 1 or exon 7 inhibited androgen-independent transcriptional activity in CWR-R1 early cells, but only siRNA targeted to AR exon 1 had this effect in CWR-R1 late cells (Figure 7c ). These data indicate that androgen independent AR activity in CWR-R1 early cells is dependent on full-length AR expression, whereas androgenindependent AR activity in CWR-R1 late cells is mediated by truncated AR variants through a mechanism that is independent of full-length AR. To investigate differential siRNA sensitivity and a differential role for full-length AR in more detail, we compared the androgen-independent growth of CWR-R1 early and CWR-R1 late cells transfected with AR-targeted siRNAs. Consistent with their selection under castrate conditions, CWR-R1 late cells displayed a rapid androgen-independent growth rate, which was inhibited by siRNA targeted to AR exon 1, but not AR exon 7 (Figure 7d ). Conversely, CWR-R1 early cells grew slowly under androgenindependent conditions during this short time-course and there was limited response to AR-targeted siRNA (Figure 6d ).
DISCUSSION
The prevalence of AR gene mutations in CRPCa reported by different groups has been variable, but appears to be low at approximately 10%. 13 --20 These data suggest that the majority of CRPCa harbors a wild-type AR gene. However, mutations have been evaluated historically by sequence analysis of AR cDNA and/ or AR coding exons, which represents only B1.5% of the 180 245-bp AR gene. 36 The identification and clinical validation of truncated AR variant synthesis as an important mechanism of PCa therapy resistance has raised the possibility that splicing disruptions may be due to non-coding AR gene alterations. Indeed, our previous work defined a B35-kb AR intragenic tandem duplication in 22Rv1 cells, which is a rational explanation for the altered splicing pattern in this cell line. 33 In this study, we have defined two additional simple AR gene structural alterations that are linked to the pathological AR splicing patterns in the LuCaP 86.2 and CWR-R1 models of PCa progression. These data, combined with MLPA analysis of additional CRPCa specimens, indicate that the prevalence of AR gene alterations in tumors resistant to ADT may be higher than previously anticipated. Although targeted methods such as MLPA are useful for identifying deletions or duplications that involve probe-binding sites, this study has illustrated that unbiased evaluation of the entire AR gene sequence and structure is a preferable approach. However, our work has also demonstrated that high-throughput approaches are challenged by substantial repeat in the AR locus. Indeed, paired-end reads diagnostic of the 35-kb 22Rv1 AR intragenic tandem duplication were not obtained in our study, despite 6000-fold maximal ontarget sequence coverage in these cells. This indicates that many AR gene structural alterations would also go undetected using larger-scale sequence capture or whole-genome sequencing approaches. 37, 38 Therefore, to define the prevalence and spectrum of the AR gene structure alterations that may exist in clinical CRPCa, methodology optimization must be a prerequisite.
Previous analysis of genome-wide copy number data from clinical CRPCa specimens suggested that complex patterns of copy number gain and copy number loss occurred along the length of the AR gene, 33 which is supported by MLPA analysis in this study. Here, we demonstrated that large deletions involving intron 1 are associated with enhanced synthesis of the truncated AR 1/2/3/CE3 variant (also referred to as AR-V7 or AR3) and a growth advantage under castrate conditions. In the CWR-R1 model, castration-mediated enrichment for cells harboring intron 1 deletion resulted in an overall population that exhibited levels of AR 1/2/3/CE3 that were equivalent to or greater than the levels of full-length AR. This is important because a recent study of surgical specimens of CRPCa bone metastases with an antibody specific for the AR NTD demonstrated that protein expression of truncated AR variants can reach similar high levels relative to full-length AR. 32 Moreover, patients with CRPCa bone metastases that displayed the highest levels of alternatively spliced, truncated AR mRNA variants had shorter cancer-specific survival after metastasis surgery than other CRPCa patients. 32 Therefore, increased expression of truncated AR variants is an important component of clinical PCa progression. The data in this study strongly suggests that alterations in the architecture of the AR gene may underlie these disruptions in normal splicing patterns. With this in mind, it is important to point out that a true 'alternative splicing' mechanism has not yet been elucidated for the AR gene. Rather, models that exhibit levels of truncated AR variant expression sufficient to drive the CRPCa phentoype (such as 22Rv1, CWR-R1 and LuCaP 86.2) have dramatic changes in the AR gene template. These AR intragenic duplications and deletions that we have defined all appear to result from homologous recombination-independent mechanisms such as microhomology-mediated break-induced replication in 22Rv1 33 and non-homologous end joining in LuCaP 86.2 and CWR-R1. Therefore, the exact locations of breakpoints in the AR locus are unlikely to be recurrent between specimens. Intriguingly, these three models each display a unique splicing signature and repertoire of truncated AR variant protein expression. Therefore, it is tempting to speculate that different patterns of AR gene alteration may give rise to different AR splicing patterns in clinical CRPCa. This would argue that a complete understanding of the role of truncated AR variants in CRPCa progression will require that individual tumors be evaluated for splicing alterations using unbiased detection methods rather than targeted approaches focused on known AR variants.
Overexpression of the AR 1/2/3/CE3 variant (also referred to as AR-V7 or AR3), the AR v567es variant, or a truncated AR variant of mouse origin (mAR-V4) in LNCaP cells can induce androgenindependent expression of AR target genes and growth under castrate conditions in vitro and in vivo. 28, 30, 31 Interestingly, treatment of these engineered LNCaP cells with the nextgeneration anti-androgen MDV3100 or knock down of full-length AR resulted in reversal of these CRPCa features. 31 These data indicate that truncated AR variants require full-length AR to support a CRPCa phenotype. However, this is in opposition to our studies with CRPCa models that endogenously express high levels of truncated AR variants and harbor apparent gain-of-function structural alterations in the AR gene. 27, 33 For example, in this study, knock down of full-length AR had no effect on androgenindependent AR activity or androgen-independent growth in latepassage CWR-R1 cells. However, knock down of AR 1/2/3/CE3 inhibited these parameters. We have also demonstrated this differential response to isoform-targeted siRNAs in the 22Rv1 cell line. 27 Conversely, early-passage CWR-R1 cells displayed modest androgen-independent growth and measurable androgen-independent AR activity, which was inhibited following knock down of full-length AR. These data demonstrate that the CWR-R1 cell line is heterogeneous and that growth conditions can have dramatic effects on the relative proportions of androgen-dependent cells and CRPCa cells, which may explain a previous report where CWR-R1 cells displayed decreased proliferation and increased apoptosis in response to full-length AR knockdown. 28 With this in mind, it is also important to note that the LuCaP 86.2 xenograft tissue evaluated in this study was propagated in an intact male mouse, and MLPA data reflected an approximate 50/50 mixture of cells with either one intact AR gene copy or one AR gene copy with a 8579-bp deletion of exons 5, 6 and 7. If the cell population harboring the 8549-bp intragenic deletion is indeed the cell population which synthesizes the AR v567es variant, these cells would not be able to synthesize full-length AR and would be truly independent of full-length AR activity. 30 Therefore, a more thorough investigation of the requirement for full-length AR is warranted, as this will provide important insights to resistance mechanisms that may circumvent clinical responses to current and next-generation therapies targeting the AR ligand-binding domain. 25 In summary, this study represents the first report of intragenic deletions involving coding and non-coding sequences in the AR gene in CRPCa, which we have linked to expression of truncated AR variants that support the CRPCa phenotype. Therefore, structural alterations in the AR gene may represent a widespread, yet previously unanticipated, mechanism of therapy resistance in PCa. Our findings provide justification for large-scale investigation of AR gene structure and splicing patterns in clinical specimens.
MATERIALS AND METHODS

PCa tissues
Genomic DNA samples from the LuCaP series of PCa xenografts and deidentified clinical CRPCa tissue were obtained from the University of Washington Prostate Cancer Biorepository, which was developed and managed by one of the co-authors (RLV) and has been described in previous publications. 30, 39, 40 De-identified prostatectomy tissue samples were obtained under the direction of the University of Minnesota BioNet tissue resource, which was developed and managed by one of the co-authors (SCS). Cores of PCa tissue (1 mm) were obtained from archival formalin-fixed, paraffin-embedded prostatectomy blocks using a tissue microarrayer (Beecher Instruments, Sun Prairie, WI, USA) and genomic DNA was isolated using a RecoverAll kit (Applied Biosystems/Ambion, Austin, TX, USA).
Cell culture
The 22Rv1 (number CRL-2505), LNCaP (number CRL-1740) and VCaP (number CRL-2876) cell lines were obtained from ATCC (Manassas, VA, USA) and cultured according to ATCC protocol. CWR22Pc cells 41 were generously provided by Dr Marja Nevalainen (Thomas Jefferson University) and cultured in RPMI 1640 supplemented with 10% fetal bovine serum, 2.5 mM Lglutamine and 0.8 nM dihydrotestosterone (Sigma, St Louis, MO, USA). CWR-R1 cells 42 were a kind gift from Dr Elizabeth Wilson (UNC Chapel Hill) and cultured in RPMI 1640 þ 10% fetal bovine serum. For androgen response experiments, cells were cultured in RPMI 1640 þ 10% steroid-depleted, charcoal-stripped serum for 48 h, treated at t ¼ 0 with 1 nM dihydrotestosterone (Sigma) or vehicle (EtOH), and then harvested at indicated time points. For long-term culture experiments, CWR-R1 cells were cultured in RPMI 1640 þ 10% charcoal-stripped serum. Cells were trypsinized and re-seeded in the appropriate medium when flasks attained 80% confluence.
Transient transfections
The CWR-R1 cell line was electroporated with siRNAs targeted to AR exon 7 (target sequence: 5 0 -GGAACUCGAUCGUAUCAUU-3 0 ) or AR exon 1 (5 0 -CAAG GGAGGUUACACCAAA-3 0 ) and/or an MMTV-LUC reporter as described. 27 Growth of electroporated cells was monitored by crystal violet staining as described. 33 Luciferase activity was measured as described. 27 Quantitative real-time RT --PCR. RNA isolation and absolute quantification RT --PCR analysis of alternatively-spliced AR mRNA isoforms was performed as described. 33 To correct for different levels of wild-type AR mRNA expression among the PCa cell lines, copy numbers of AR mRNA isoforms were scaled relative to wild-type AR mRNA copy number in each cell line (set to 1). For relative quantification RT --PCR, fold change in expression levels were determined by the comparative Ct method using the equation 2 -DDCt .
Genomic PCR. Genomic PCR was performed as described, 33 using primer pairs listed in Supplementary Table 6 .
Western blot
Western blotting with AR NTD (N-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA), AR CTD (Santa Cruz C-19), ERK-2 (Santa Cruz D-2) and ARV-7 (number AG10008, Precision Antibody, Columbia, MD, USA) antibodies was performed as described. 33 Multiplex ligation-dependent probe assay MLPA for AR coding sequence was performed using a commercially available kit (P074, MRC Holland, Amsterdam, The Netherlands) as per the manufacturer's protocol. Briefly, 100 ng of genomic DNA was hybridized at 60 1C for 18 h with MLPA probemix. Hybridized probes were ligated and amplified by PCR with labeled universal primers provided with the MLPA kit. PCR reactions were diluted 1:10 in formamide containing ROX-500 size standards (Applied Biosystems, Carlsbad, CA, USA), denatured and resolved by capillary electrophoresis using a Genetic Analyzer 3130XL (Applied Biosystems). Electropherogram peak areas were obtained using Peak Scanner software (Applied Biosystems). Peak areas for samples and calibration control (HPV-7 prostate epithelial cell genomic DNA) were block-normalized using X-chromosome p-arm controls and then normalized to HPV-7 copy number with the inference that the HPV-7 genome contains one copy of the AR gene. MLPA for AR intron sequences was performed using the exact same protocol with a commercially available reagent kit (EK1, MRC Holland) and custom-designed oligonucleotide probes ( Supplementary Table 7 ). Probe pairs that each displayed copy number values outside of one s.d. from the mean copy number of all AR locus probes from two independent experiments were determined to have increased or decreased copy number at that location.
Paired-end library creation, sequence capture and next-generation sequencing Genomic DNA from CWR22Pc, 22Rv1 and CWR-R1 cells was fragmented using an S220 ultra-sonicator (Covaris, Woburn, MA, USA) with Agilent SureSelect parameters. A Bioanalyzer DNA 1000 chip (Agilent, Santa Clara, CA, USA) was used to verify DNA samples sheared with fragment peaks between 150 --200 bp. Paired-end sequencing libraries were generated from sheared DNA samples using a SureSelect Library Preparation Kit (Agilent) and amplified for sequence capture as per the manufacturer's protocol. The amplified DNA libraries were hybridized and captured using overlapping, tiled SureSelect baits (Agilent) custom-designed to provide two times coverage of non-repetitive regions of the AR locus (Supplementary Table 8 ). Target-enriched libraries were amplified for 16-cycles to add index tags and generate sufficient template for flowcell clustering. Final libraries were quantified via quantitative PCR (Kapa Biosystems, Woburn, MA, USA), normalized and pooled before clustering on a single lane of a flowcell. The flowcell was loaded on a Genome Analyzer IIx (GAIIx, Illumina, San Diego, CA, USA) for paired-end sequencing at 76 cycles (2 Â 76 bp). Data analysis methodology is provided as Supplemental Information.
